Floatz Rating
B61/100
Confidence
Indicative
Sponsor
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05150236CT.gov EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC | — | Unknown | — | — | — |
NCT04388852CT.gov DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers | — | Active Not Recruiting | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT05655715CT.gov Checkpoint Inhibitors and SBRT for MCRPC | — | Completed | — | — | — |
NCT03866382CT.gov Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | — | Recruiting | — | — | — |
NCT03879122CT.gov A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer | — | Unknown | — | — | — |
NCT03477864CT.gov Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer | — | Withdrawn | — | — | — |
NCT03651271CT.gov Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer | — | Completed | — | — | — |
NCT03532217CT.gov Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer | — | Completed | — | — | — |
NCT03061539CT.gov Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature | — | Active Not Recruiting | — | — | — |
Show 21 more trialsShow fewer
NCT03333616CT.gov Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors | — | Active Not Recruiting | — | — | — |
NCT03098160CT.gov Immunotherapy Study of Evofosfamide in Combination With Ipilimumab | — | Unknown | — | — | — |
NCT02985957CT.gov A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650) | — | Completed | — | — | — |
NCT02601014CT.gov Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 | — | Completed | — | — | — |
NCT01530984CT.gov Ipilimumab and GMCSF Immunotherapy for Prostate Cancer | — | Withdrawn | — | — | — |
NCT02423928CT.gov Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer | — | Completed | — | — | — |
NCT02279862CT.gov Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive | — | Completed | — | — | — |
NCT02113657CT.gov T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT01804465CT.gov Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer | — | Completed | — | — | — |
NCT01832870CT.gov Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer | — | Completed | — | — | — |
NCT01688492CT.gov Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT01498978CT.gov Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT01377389CT.gov Ipilimumab + Androgen Depravation Therapy in Prostate Cancer | — | Terminated | — | — | — |
NCT01194271CT.gov Neoadjuvant Ipilimumab in Prostate Cancer | — | Completed | — | — | — |
NCT01057810CT.gov Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer | — | Completed | — | — | — |
NCT00861614CT.gov Study of Immunotherapy to Treat Advanced Prostate Cancer | — | Completed | — | — | — |
NCT00323882CT.gov Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer | — | Completed | — | — | — |
NCT01510288CT.gov Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer | — | Terminated | — | — | — |
NCT00170157CT.gov Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer | — | Completed | — | — | — |
NCT00064129CT.gov Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT00050596CT.gov Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ipilimumab (this asset) | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | P3 | B · 61 |
| Avodart | Bay State Clinical Trials, Inc. | P4 | BBB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Propofol | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Degarelix | Bayer | P4 | BBB |
| Flotufolastat F 18 | Washington University School of Medicine | P4 | BB |
| AVOLVE | Masonic Cancer Center, University of Minnesota | P4 | BB |
| Estramustine | The University of Texas Health Science Center, Houston | P3 | BB |
| Pasireotide | RECORDATI GROUP | P4 | BB |
+42 more in the Prostate Cancer cohort
Other indications for Ipilimumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Neoplasm | — | P3 | BB · 71 |
| Melanoma | — | P4 | BB · 69 |
| Cutaneous Melanoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ipilimumab in Prostate Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ipilimumab-prostate-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →